BR112012019475A2 - "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra - Google Patents

"uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra

Info

Publication number
BR112012019475A2
BR112012019475A2 BR112012019475A BR112012019475A BR112012019475A2 BR 112012019475 A2 BR112012019475 A2 BR 112012019475A2 BR 112012019475 A BR112012019475 A BR 112012019475A BR 112012019475 A BR112012019475 A BR 112012019475A BR 112012019475 A2 BR112012019475 A2 BR 112012019475A2
Authority
BR
Brazil
Prior art keywords
antibody
hnscc
kit
sample
detecting
Prior art date
Application number
BR112012019475A
Other languages
English (en)
Other versions
BR112012019475A8 (pt
Inventor
Luis A G Da Cruz
University Of Miami
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43858306&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012019475(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012019475A2 publication Critical patent/BR112012019475A2/pt
Publication of BR112012019475A8 publication Critical patent/BR112012019475A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

abstract not avaible
BR112012019475A 2010-02-04 2011-02-02 uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra BR112012019475A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30144910P 2010-02-04 2010-02-04
PCT/EP2011/051436 WO2011095498A1 (en) 2010-02-04 2011-02-02 A monoclonal antibody to cd44 for use in the treatment of head and neck squamous cell carcinoma

Publications (2)

Publication Number Publication Date
BR112012019475A2 true BR112012019475A2 (pt) 2017-01-10
BR112012019475A8 BR112012019475A8 (pt) 2017-12-26

Family

ID=43858306

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012019475A BR112012019475A8 (pt) 2010-02-04 2011-02-02 uso de um anticorpo monoclonal anti-cd44, anticorpo monoclonal anti-cd44, anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra

Country Status (29)

Country Link
US (2) US20130224108A1 (pt)
EP (1) EP2531527B1 (pt)
JP (2) JP5763105B2 (pt)
KR (1) KR20130042466A (pt)
CN (1) CN102741292B (pt)
AU (1) AU2011212485B2 (pt)
BR (1) BR112012019475A8 (pt)
CA (1) CA2786337A1 (pt)
CL (1) CL2012001980A1 (pt)
CR (1) CR20120429A (pt)
DK (1) DK2531527T3 (pt)
EC (1) ECSP12012138A (pt)
ES (1) ES2460945T3 (pt)
HR (1) HRP20140513T1 (pt)
IL (1) IL220092A (pt)
MA (1) MA34010B1 (pt)
MX (1) MX2012008699A (pt)
MY (1) MY157532A (pt)
NZ (1) NZ600079A (pt)
PE (1) PE20130380A1 (pt)
PL (1) PL2531527T3 (pt)
PT (1) PT2531527E (pt)
RS (1) RS53327B (pt)
RU (1) RU2599447C2 (pt)
SG (2) SG182704A1 (pt)
SI (1) SI2531527T1 (pt)
TW (1) TW201130512A (pt)
WO (1) WO2011095498A1 (pt)
ZA (1) ZA201205649B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2599447C2 (ru) * 2010-02-04 2016-10-10 Юниверсити Оф Майами Моноклональные антетела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи
KR20140090997A (ko) * 2011-10-26 2014-07-18 더 리전트 오브 더 유니버시티 오브 캘리포니아 B-세포 만성 림프구성 백혈병 및 다른 혈액학적 악성종양의 치료를 위한 cd44 단일클론 항체
WO2013083497A1 (en) * 2011-12-06 2013-06-13 F. Hoffmann-La Roche Ag Antibody formulation
US20150044232A1 (en) * 2013-06-12 2015-02-12 Hoffmann-La Roche Inc. Markers for the responsiveness to anti-cd44 antibodies
MX2016001439A (es) * 2013-07-31 2016-07-05 Univ Miami Composiciones y metodos para identificar un riesgo de cancer en un sujeto.
WO2015076425A1 (ja) * 2013-11-25 2015-05-28 リンク・ジェノミクス株式会社 新規モノクローナル抗体
KR102215384B1 (ko) * 2014-06-11 2021-02-15 (재) 스크립스코리아항체연구원 CD44v3 도메인 3 및 도메인 6 특이적 단일클론 항체 및 그 용도
TWI535452B (zh) 2015-01-23 2016-06-01 長庚醫療財團法人 使用抗－ｃｄ４４中和抗體來治療和／或預防心房顫動
JP2023526529A (ja) 2020-05-19 2023-06-21 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
JP2024512324A (ja) * 2021-03-05 2024-03-19 ジーオー セラピューティクス，インコーポレイテッド 抗グリコｃｄ４４抗体およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE19545472A1 (de) * 1995-12-06 1997-06-12 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Plattenepithelkarzinomen
UY24389A1 (es) * 1995-12-06 2001-10-25 Karlsruhe Forschzent Composición farmacéutica para el tratamiento de carcinoma de epitelio plano
US7252821B2 (en) 1999-10-08 2007-08-07 Arius Research Inc. Cancerous disease modifying antibodies
US20050100542A1 (en) 1999-10-08 2005-05-12 Young David S. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8048416B2 (en) * 1999-10-08 2011-11-01 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20090004103A1 (en) * 1999-10-08 2009-01-01 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD44
US6180357B1 (en) 1999-10-08 2001-01-30 Arius Research, Inc. Individualized patient-specific anti-cancer antibodies
CZ20033476A3 (cs) 2001-05-18 2004-05-12 Boehringeráingelheimáinternationalágmbh Protilátky specifické pro CD@@v
US20030103985A1 (en) * 2001-05-18 2003-06-05 Boehringer Ingelheim International Gmbh Cytotoxic CD44 antibody immunoconjugates
US20040110933A1 (en) * 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
EP1532984A1 (en) * 2003-11-19 2005-05-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti CD44 antibodies for eradicating stem cells in acute myeloid leukemia
RU2599447C2 (ru) * 2010-02-04 2016-10-10 Юниверсити Оф Майами Моноклональные антетела к cd44, предназначенные для применения при лечении плоскоклеточной карциномы головы и шеи

Also Published As

Publication number Publication date
CR20120429A (es) 2012-12-06
EP2531527A1 (en) 2012-12-12
JP6037149B2 (ja) 2016-11-30
SG10201505118PA (en) 2015-07-30
JP2013518848A (ja) 2013-05-23
BR112012019475A8 (pt) 2017-12-26
CN102741292B (zh) 2015-10-21
EP2531527B1 (en) 2014-03-19
ECSP12012138A (es) 2012-09-28
HRP20140513T1 (hr) 2014-07-18
IL220092A (en) 2016-02-29
CN102741292A (zh) 2012-10-17
KR20130042466A (ko) 2013-04-26
JP5763105B2 (ja) 2015-08-12
AU2011212485A1 (en) 2012-07-19
ES2460945T3 (es) 2014-05-16
RU2012137380A (ru) 2014-03-10
ZA201205649B (en) 2015-01-28
SG182704A1 (en) 2012-08-30
PL2531527T3 (pl) 2014-08-29
RU2599447C2 (ru) 2016-10-10
TW201130512A (en) 2011-09-16
MY157532A (en) 2016-06-15
JP2015155409A (ja) 2015-08-27
US20150374848A1 (en) 2015-12-31
IL220092A0 (en) 2012-09-24
NZ600079A (en) 2013-07-26
PE20130380A1 (es) 2013-03-30
WO2011095498A1 (en) 2011-08-11
MX2012008699A (es) 2012-09-12
PT2531527E (pt) 2014-05-16
CL2012001980A1 (es) 2012-11-23
CA2786337A1 (en) 2011-08-11
SI2531527T1 (sl) 2014-07-31
US20130224108A1 (en) 2013-08-29
DK2531527T3 (da) 2014-05-05
MA34010B1 (fr) 2013-02-01
RS53327B (en) 2014-10-31
AU2011212485B2 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
BR112012019475A2 (pt) "uso de um anticorpo monoclonal anti-cd 44 anticorpo anti-cd44 humanizado e kit para a detecção da presença de hnscc em uma amostra
CR20130621A (es) Anticuerpos anti-angptl3 y usos de los mismos
BR112015023239A8 (pt) ensaio de combinação de anticorpo-antígeno de hcv e métodos e composições para uso do mesmo
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
BRPI0813514A2 (pt) anticorpos anti-cd79b humanizados e imunoconjugados e métodos de uso
ECSP11011239A (es) Proteínas ligadoras il-1
BR112013023540A2 (pt) anticorpo, kit e método para a determinação de peptídeos amilóides
BR112014008382A2 (pt) anticorpo especificamente ligando a epítope no domínio sema do c-met
CL2014000590A1 (es) Anticuerpo o fragmento de union a antigeno del mismo que se une a pcsk9 humana; composicion farmaceutica que lo comprende; y su uso para tratar hiperlipidemia o hipercolesterolemia.
SG10201408392PA (en) Methods of determining patient response by measurement of her-3
BRPI0906435A2 (pt) anticorpos anti-cd79b e imunoconjugados e métodos de uso
BR112012007365A2 (pt) proteínas de ligação à il-1
CO6640258A2 (es) Formulaciones de anticuerpos de alta concentración
WO2010065568A3 (en) METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
BRPI0811526A2 (pt) uso de um anticorpo monoclonal, quimérico, humanizado ou humano que liga o il-5r, anticorpo anti-il-5r isolado, e, epítopo isolado de il-5r alfa
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
CL2014000574A1 (es) Anticuerpo monoclonal humanizado que se une al complejo aßtcr/cd3 humano.
BRPI0906478A2 (pt) anticorpo anti-nr10 e uso do mesmo
BR112014012590A8 (pt) Anticorpos anti-cd98 e métodos de uso dos mesmos
BR112015022123A8 (pt) Anticorpos, fragmentos de ligação ao antígeno dos mesmos que se ligam especificamente à hepcidina ou um peptídeo de hepcidina, uso, meio contentor e kit
CR20140382A (es) Anticuerpos anti-lrp5 y metodos de uso
BR112012033163A2 (pt) ''anticorpos monoclonais, linhagens celulares, usos de um anticorpo, kit, métodos para detectar um anticorpo, composição de anticorpo e uso de uma composição de anticorpo''
CR20110559A (es) Anticuerpos específicos para cadherina-17

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25A Requested transfer of rights approved

Owner name: UNIVERSITY OF MIAMI (US)

B25G Requested change of headquarter approved

Owner name: UNIVERSITY OF MIAMI (US)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2499 DE 27/11/2018.